Publication

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE).

Journal Paper/Review - Jul 15, 2022

Units
PubMed
Doi
Contact

Citation
Sudano I, Mach F, Moccetti T, Burkard T, Fahe C, Delabays A, Rickli H, Keller P, Dopheide J, Bodenmann S, Fiolka T, Ehret G, Spirk D. Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE). Front Cardiovasc Med 2022; 9:953040.
Type
Journal Paper/Review (English)
Journal
Front Cardiovasc Med 2022; 9
Publication Date
Jul 15, 2022
Issn Print
2297-055X
Pages
953040
Brief description/objective

Low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). In confirmatory trials, proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab substantially lowered LDL-C and reduced cardiovascular morbidity and mortality. However, the routine clinical use of alirocumab in Switzerland has not yet been studied.